Uticaj pola na korelaciju biohemijskih parametara sa težinom KOVID pneumonije i potrebe za primenom kiseonične/mehaničke potpore
Uticaj pola na korelaciju biohemijskih parametara sa tezinom KOVID pneumonije
Sažetak
Uvod: Pandemija COVID-19 je izazvala globalni medicinski, ekonomski i socijalni problem. Visoka stopa zaraze, heterogena klinička slika, nedostatak prethodnih podataka i nepostojanje standardizovanog protokola lečenja su doveli do potrebe za daljom analizom, kako bi se ovi problem prevazišli u slučaju potencijalne nove pandemije. Analizirali smo moguću korelaciju između pola, laboratorijskih nalaza i težine bolesti sa potrebom za kiseonikom ili mehaničkom ventilacijom.
Metode: Uključeno je 100 pacijenata sa potvrđenom infekcijom virusom SARS-CoV-2. Zabeležene su osnovne karakteristike koje su uključivale starost, pol, istoriju pušenja, BMI, terapiju kiseonikom ili potrebu za mehaničkom ventilacionom potporom. Vrsta i težina radiografskog nalaza utvrđena je skenerom grudnog koša.
Rezultati:Većina naših pacijenata bila je starija od 61 godine (58.6%), muškog pola (57.6%) i imali su teške radiografske manifestacije COVID-19 infekcije (bilateralna pneumonija 29.3%, ARDS 35.4%), a samo 20.2% nije zahtevalo dodatnu primenu kiseonične terapije. U pogledu pola i laboratorijskih nalaza, muškarci su pokazali statistički značajno veće vrednosti CRP, limfocita, LDH i feritina (96.4 vs 87.1, p=0.014; 1.17 vs 0.84, p=0.048; 674.8 vs 609.1, p=0.031; 1263 vs 578.4, p=0.001). Teži radiološki nalaz pokazao je pozitivnu korelaciju sa potrebom za HFNC i/ili (N)IMV (p=0.021 i p=0.032), kao i sa višim vrednostima leukocita, LDH i feritina (p=0.042, p=0.035 i p=0.017).
Zaključak: Prisutne su razlike između kliničke manifestacije bolesti i analiziranih laboratorijskih markera između polova; razlika najverovatnije postoji i između drugih laboratorijskih parametara, je su neophodna dalja istraživanja kako bi isti otkrili.
Reference
1. Statement on the fourteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Available at https://www.who.int/news/item/30-01- 2023-statement-on-the-fourteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497–506.
4. Thomas Craig KJ, Rizvi R, Willis VC, Kassler WJ, Jackson GP. Effectiveness of Contact Tracing for Viral Disease Mitigation and Suppression: Evidence-Based Review. JMIR Public Health Surveill 2021; 7: e32468.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–1242
6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229): 1033–4.
7. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020;395:1763–70.
8. Letelier P Encina N, Morales P, Riffo A, Silva H, Riquelme I, Guzmán N. Role of biochemical markers in the monitoring of COVID-19 patients. J Med Biochem 2021; 40 (2) 115–28.
9. Tomar B, Anders H-J, Desai J, Mulay SR. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells 2020; 9: 1383.
10. World Health Organization. SUBJECT IN FOCUS: WHO Global Case-Based Surveillance for Human Infection with Coronavirus Disease (COVID-19).; 2020. Accessed May 23, 2020 at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2
11. Amgalan A, Malinowski AK, Othman M. COVID-19 and Sex-/Gender-Specific Differences: Understanding the Discrimination. Semin Thromb Hemost. 2021 Jun;47(4):341-347.
12. COVID-19 sex-disaggregated data tracker – Global Health 50/50. Accessed May 23, 2020 at: https://globalhealth5050.org/covid19/sex-disaggregated-data-tracker/#1587645651236-8a62beb3-4a03
13. Walter LA, McGregor AJ. Sex- and gender-specific observations and implications for COVID-19. West J Emerg Med 2020; 21 (03) 507-509
14. Hewagama A, Patel D, Yarlagadda S, Strickland FM, Richardson BC. Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis. Genes Immun 2009; 10 (05) 509-516
15. Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol 2018; 9: 2279
16. Matsuyama S, Nao N, Shirato K. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 2020; 117 (13) 7001-7003
17. Meng Y., Wu P., Lu W. Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: a retrospective study of 168 severe patients. PLoS Pathog. 2020;16(4):e1008520.
18. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Eur J Allergy Clin Immunol 2020; 75: 1730–41.
19. Huang I., Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:36.
20. Ahnach M, Zbiri S, Nejjari S, Austin F, Elkettani C. C-reactive protein as an early predictor of COVID-19 severity. J Med Biochem. 2020;39:500–7
21. Luo W, Zhang JW, Zhang W, Lin YL, Wang Q. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms. J Med Virol. 2021;93:89–91
22. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29:401‐409.
23. Carcillo JA, Sward K, Halstead ES, et al. A systemic inflammation mortality risk assessment contingency table for severe sepsis. Pediatr Crit Care Med. 2017;18:143‐150.
24. Huang Y, Lu Y, Huang YM, Wang M, Ling W, Sui Y, Zhao HL. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020 Dec;113:154378
25. Huang J.F., Wang X.B., Zheng K.I., Liu W.Y., Chen J.J., George J. Letter to the editor: obesity hypoventilation syndrome and severe COVID-19. Metabolism. 2020;108:154249.
26. Shi L., Wang Y., Wang Y., Duan G., Yang H. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19 [published online ahead of print, 2020 May 15] J Infect. 2020;S0163-4453(20):30288.
Sva prava zadržana (c) 2024 Jelena Janković, Mihailo Stjepanovic, Nikola Maric, Slobodan Belic
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.